600% roi in 3 months, page-6

True SoccerMom, the shareholders weren’t putting necessary cash into BOS and the company had no option but to seek private money. When Peter Steinberg announced the Institutional Placement the share price rallied to our recent highs. We seemed to be back in the game. Observing the mysterious financier take hostile control of BOS has caused some nervousness in the share price.

Many stakeholders believe Biosignal’s IP can be commercialised and CBTE promises to do that. If you believe our product will be successful, following our IP into CBTE with as big a shareholding as possible may be the best option. Holding their shares exposes us to returns if CBTE succeeds. I would expect to own the shares unconditionally, that is, our position can not be unwound should the value of the IP be later contested or revised by CBTE. It is commonplace for a discovery to be ‘improved’ in some manner to avoid claims by the discoverer.

CBTE succeeding with our IP may be more likely than BOS, without its IP, succeeding in its new venture.

Cash received from the sale of our shares to CBTE will be spent immediately. What would D’Sylva have us buy? Something of value we hope. Would it be too cynical to anticipate something related to himself, or another company to feed to CBTE? Let’s just say it is unknown and we will have to trust the directors and wait and see.

The prize is Biosignal’s IP. That is what D’Sylva and CBTE want. What they want for BOS is unclear.

Previously Biosignal sought to get from industry multiple non-exclusive licensing deals in defined areas of application. BOS would make money on the royalties and fees and keep ownership of the IP. The effect of loss or dispute with any one company was minimised. BOS is unquestionably on shaky ground but selling the shop, as we are being asked to do, is still a big ask. The possibly awkward duty of the incumbent directors is not to Empire Investments who appointed them, but to Biosignal, and cut us the best deal possible.